In addition, CDK4/6i have been shown to increase tumor cell antigen presentation via upregulation of the major histocompatibility complex (MHC) class I, thereby enhancing cancer cell immunogenicity and recognition by the immune system [25,26]. This evidence concerns the gene CDK4 and neoplasm.